| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 19 | 2023 | 344 | 7.650 |
Why?
|
| Skin Ulcer | 9 | 2021 | 129 | 4.760 |
Why?
|
| HIV Infections | 161 | 2024 | 17165 | 2.910 |
Why?
|
| Anti-HIV Agents | 84 | 2023 | 4491 | 2.850 |
Why?
|
| Raynaud Disease | 6 | 2022 | 79 | 2.770 |
Why?
|
| Fingers | 8 | 2021 | 506 | 2.700 |
Why?
|
| HIV-1 | 80 | 2023 | 6849 | 1.920 |
Why?
|
| CD4 Lymphocyte Count | 63 | 2023 | 2569 | 1.800 |
Why?
|
| HIV Protease Inhibitors | 24 | 2022 | 432 | 1.640 |
Why?
|
| Antiretroviral Therapy, Highly Active | 39 | 2023 | 1894 | 1.530 |
Why?
|
| Reverse Transcriptase Inhibitors | 29 | 2023 | 618 | 1.420 |
Why?
|
| Ritonavir | 26 | 2022 | 328 | 1.420 |
Why?
|
| Viral Load | 53 | 2024 | 3322 | 1.410 |
Why?
|
| Nevirapine | 23 | 2023 | 273 | 1.360 |
Why?
|
| Zidovudine | 27 | 2021 | 624 | 1.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 25 | 2021 | 1348 | 1.070 |
Why?
|
| Antiviral Agents | 18 | 2024 | 3061 | 1.020 |
Why?
|
| RNA, Viral | 51 | 2023 | 2838 | 1.010 |
Why?
|
| Tuberculosis | 10 | 2024 | 2001 | 0.950 |
Why?
|
| Pregnancy Complications, Infectious | 27 | 2023 | 2125 | 0.950 |
Why?
|
| Anti-Retroviral Agents | 20 | 2023 | 1779 | 0.910 |
Why?
|
| Osteomyelitis | 3 | 2021 | 407 | 0.820 |
Why?
|
| Calcinosis | 3 | 2019 | 1476 | 0.790 |
Why?
|
| Acquired Immunodeficiency Syndrome | 22 | 2023 | 2197 | 0.700 |
Why?
|
| Vascular Diseases | 3 | 2018 | 1182 | 0.700 |
Why?
|
| Microscopic Angioscopy | 2 | 2016 | 20 | 0.690 |
Why?
|
| Erectile Dysfunction | 1 | 2023 | 452 | 0.670 |
Why?
|
| Models, Statistical | 15 | 2017 | 5075 | 0.670 |
Why?
|
| Clinical Trials as Topic | 22 | 2019 | 8056 | 0.670 |
Why?
|
| Takayasu Arteritis | 1 | 2020 | 95 | 0.660 |
Why?
|
| Drug Resistance, Viral | 14 | 2024 | 859 | 0.650 |
Why?
|
| Latent Tuberculosis | 4 | 2023 | 224 | 0.650 |
Why?
|
| Randomized Controlled Trials as Topic | 20 | 2023 | 10344 | 0.640 |
Why?
|
| Hand Joints | 1 | 2019 | 58 | 0.630 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 6 | 2023 | 930 | 0.600 |
Why?
|
| Humans | 297 | 2024 | 760621 | 0.590 |
Why?
|
| Giant Cell Arteritis | 1 | 2020 | 295 | 0.540 |
Why?
|
| Connective Tissue Diseases | 2 | 2016 | 286 | 0.530 |
Why?
|
| Thermography | 1 | 2016 | 63 | 0.530 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 3986 | 0.510 |
Why?
|
| Hemoglobinopathies | 1 | 2016 | 96 | 0.500 |
Why?
|
| Botswana | 16 | 2023 | 1040 | 0.450 |
Why?
|
| Central Nervous System Stimulants | 1 | 2022 | 1174 | 0.450 |
Why?
|
| Adult | 140 | 2024 | 219994 | 0.450 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2020 | 786 | 0.450 |
Why?
|
| HIV | 13 | 2024 | 1579 | 0.440 |
Why?
|
| Female | 179 | 2024 | 391270 | 0.430 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2023 | 831 | 0.430 |
Why?
|
| Research Design | 10 | 2021 | 6180 | 0.430 |
Why?
|
| Mass Casualty Incidents | 1 | 2015 | 179 | 0.420 |
Why?
|
| HIV Seropositivity | 5 | 2022 | 955 | 0.420 |
Why?
|
| Blood Coagulation Disorders | 1 | 2016 | 349 | 0.420 |
Why?
|
| Copper | 1 | 2015 | 368 | 0.400 |
Why?
|
| Male | 149 | 2024 | 359744 | 0.400 |
Why?
|
| Fibrosis | 2 | 2020 | 2042 | 0.400 |
Why?
|
| Selenium | 1 | 2015 | 416 | 0.390 |
Why?
|
| Myositis | 1 | 2015 | 269 | 0.390 |
Why?
|
| Isoniazid | 4 | 2024 | 283 | 0.390 |
Why?
|
| Focus Groups | 3 | 2023 | 1378 | 0.380 |
Why?
|
| Didanosine | 12 | 2007 | 151 | 0.380 |
Why?
|
| Quality of Life | 8 | 2022 | 13308 | 0.380 |
Why?
|
| Rheumatic Diseases | 2 | 2016 | 639 | 0.370 |
Why?
|
| Lamivudine | 9 | 2021 | 363 | 0.370 |
Why?
|
| Risk-Taking | 3 | 2015 | 998 | 0.360 |
Why?
|
| Troponin I | 1 | 2015 | 638 | 0.360 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 1299 | 0.360 |
Why?
|
| Cost of Illness | 1 | 2020 | 1940 | 0.350 |
Why?
|
| Influenza, Human | 5 | 2020 | 1528 | 0.350 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 861 | 0.340 |
Why?
|
| Sex Characteristics | 3 | 2020 | 2629 | 0.340 |
Why?
|
| Troponin T | 1 | 2015 | 774 | 0.340 |
Why?
|
| Pyrimidinones | 7 | 2011 | 384 | 0.340 |
Why?
|
| Rifampin | 5 | 2023 | 340 | 0.330 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 1023 | 0.330 |
Why?
|
| Data Interpretation, Statistical | 5 | 2016 | 2696 | 0.330 |
Why?
|
| Drug Therapy, Combination | 33 | 2024 | 6498 | 0.330 |
Why?
|
| Ribavirin | 4 | 2019 | 396 | 0.320 |
Why?
|
| Treatment Failure | 7 | 2019 | 2648 | 0.320 |
Why?
|
| Oseltamivir | 3 | 2020 | 76 | 0.320 |
Why?
|
| Typhoid Fever | 2 | 2021 | 195 | 0.310 |
Why?
|
| Incidence | 15 | 2023 | 21392 | 0.310 |
Why?
|
| Treatment Outcome | 60 | 2023 | 65017 | 0.310 |
Why?
|
| Qualitative Research | 4 | 2023 | 2963 | 0.300 |
Why?
|
| Radiography | 1 | 2019 | 6965 | 0.300 |
Why?
|
| Piperazines | 8 | 2020 | 2525 | 0.290 |
Why?
|
| Drug Dosage Calculations | 1 | 2008 | 118 | 0.290 |
Why?
|
| Monitoring, Physiologic | 2 | 2010 | 1784 | 0.290 |
Why?
|
| Sample Size | 2 | 2021 | 840 | 0.290 |
Why?
|
| Plasma | 5 | 2019 | 584 | 0.290 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2022 | 3701 | 0.280 |
Why?
|
| Pyrimidines | 9 | 2022 | 3016 | 0.280 |
Why?
|
| Middle Aged | 65 | 2024 | 220352 | 0.280 |
Why?
|
| Infant, Newborn | 35 | 2024 | 26181 | 0.270 |
Why?
|
| Biometry | 7 | 2006 | 559 | 0.270 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2023 | 1903 | 0.270 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 2477 | 0.270 |
Why?
|
| Infant | 47 | 2024 | 36060 | 0.260 |
Why?
|
| Self Report | 3 | 2021 | 3711 | 0.260 |
Why?
|
| Benzoxazines | 4 | 2020 | 309 | 0.260 |
Why?
|
| Patient Participation | 1 | 2015 | 1439 | 0.260 |
Why?
|
| Antibodies, Viral | 6 | 2024 | 3143 | 0.260 |
Why?
|
| Antitubercular Agents | 5 | 2024 | 1373 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3205 | 0.250 |
Why?
|
| Observation | 1 | 2007 | 312 | 0.250 |
Why?
|
| Pregnancy | 40 | 2024 | 29749 | 0.240 |
Why?
|
| Anemia | 4 | 2023 | 1511 | 0.240 |
Why?
|
| Adaptation, Psychological | 3 | 2023 | 2628 | 0.240 |
Why?
|
| Hepatitis C | 4 | 2019 | 1579 | 0.240 |
Why?
|
| Premature Birth | 4 | 2024 | 1771 | 0.240 |
Why?
|
| Bayes Theorem | 7 | 1999 | 2326 | 0.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2022 | 4353 | 0.230 |
Why?
|
| Stroke | 3 | 2020 | 9962 | 0.230 |
Why?
|
| Diagnostic Errors | 2 | 2015 | 1266 | 0.230 |
Why?
|
| Patient Selection | 5 | 2019 | 4283 | 0.230 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 4433 | 0.230 |
Why?
|
| Cluster Analysis | 2 | 2021 | 2698 | 0.220 |
Why?
|
| Meta-Analysis as Topic | 5 | 1997 | 1376 | 0.220 |
Why?
|
| Survival Analysis | 7 | 2014 | 10182 | 0.220 |
Why?
|
| Contact Tracing | 3 | 2022 | 268 | 0.220 |
Why?
|
| Energy Intake | 4 | 2015 | 2129 | 0.220 |
Why?
|
| Disability Evaluation | 3 | 2020 | 1826 | 0.220 |
Why?
|
| Ulcer | 2 | 2021 | 204 | 0.220 |
Why?
|
| Endpoint Determination | 3 | 2014 | 597 | 0.210 |
Why?
|
| Adrenergic Antagonists | 1 | 2022 | 26 | 0.210 |
Why?
|
| Cardiomyopathies | 1 | 2015 | 1952 | 0.210 |
Why?
|
| Scleroderma, Limited | 1 | 2022 | 8 | 0.210 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 15840 | 0.210 |
Why?
|
| Scleroderma, Diffuse | 1 | 2022 | 18 | 0.210 |
Why?
|
| Iron, Dietary | 1 | 2023 | 148 | 0.210 |
Why?
|
| Probability | 6 | 2016 | 2475 | 0.210 |
Why?
|
| Nelfinavir | 3 | 2008 | 68 | 0.200 |
Why?
|
| Receptors, Chemokine | 4 | 2008 | 655 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.200 |
Why?
|
| Breast Feeding | 4 | 2017 | 1355 | 0.200 |
Why?
|
| Smoke | 2 | 2014 | 236 | 0.200 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2010 | 326 | 0.200 |
Why?
|
| Child, Preschool | 40 | 2022 | 42063 | 0.200 |
Why?
|
| Chemoprevention | 2 | 2017 | 326 | 0.200 |
Why?
|
| Uridine Monophosphate | 2 | 2019 | 68 | 0.200 |
Why?
|
| Myocardium | 1 | 2015 | 4700 | 0.200 |
Why?
|
| Fibrinolytic Agents | 2 | 2012 | 2167 | 0.200 |
Why?
|
| Logistic Models | 9 | 2021 | 13314 | 0.200 |
Why?
|
| Family Characteristics | 4 | 2020 | 1001 | 0.200 |
Why?
|
| Inulin | 1 | 2021 | 68 | 0.200 |
Why?
|
| Ischemia | 2 | 2022 | 1893 | 0.190 |
Why?
|
| Prebiotics | 1 | 2021 | 41 | 0.190 |
Why?
|
| Regression Analysis | 9 | 2010 | 6360 | 0.190 |
Why?
|
| Air Pollutants, Occupational | 2 | 2014 | 407 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 20509 | 0.190 |
Why?
|
| Airway Remodeling | 1 | 2022 | 134 | 0.190 |
Why?
|
| Sputum | 2 | 2021 | 503 | 0.190 |
Why?
|
| Fluorenes | 2 | 2019 | 156 | 0.190 |
Why?
|
| Aged | 23 | 2024 | 169152 | 0.190 |
Why?
|
| Thromboembolism | 1 | 2008 | 1017 | 0.190 |
Why?
|
| Salmonella typhi | 2 | 2021 | 199 | 0.190 |
Why?
|
| Insurance Claim Review | 1 | 2005 | 738 | 0.190 |
Why?
|
| Pandemics | 2 | 2023 | 8624 | 0.190 |
Why?
|
| Body Fluids | 1 | 2022 | 319 | 0.180 |
Why?
|
| Double-Blind Method | 23 | 2023 | 12427 | 0.180 |
Why?
|
| Malpractice | 1 | 2005 | 556 | 0.180 |
Why?
|
| Puberty | 2 | 2020 | 498 | 0.180 |
Why?
|
| Indinavir | 4 | 2010 | 73 | 0.180 |
Why?
|
| Confidence Intervals | 4 | 2013 | 2932 | 0.180 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2015 | 4555 | 0.180 |
Why?
|
| Abortion, Spontaneous | 2 | 2024 | 530 | 0.180 |
Why?
|
| Scleroderma, Localized | 1 | 2021 | 87 | 0.170 |
Why?
|
| Rotavirus Vaccines | 1 | 2020 | 62 | 0.170 |
Why?
|
| Tuberculin Test | 4 | 2023 | 206 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 5 | 2016 | 2496 | 0.170 |
Why?
|
| Receptors, CCR5 | 5 | 2008 | 488 | 0.170 |
Why?
|
| Infection Control | 2 | 2020 | 983 | 0.170 |
Why?
|
| Methylamines | 1 | 2021 | 138 | 0.170 |
Why?
|
| Ebolavirus | 1 | 2022 | 251 | 0.170 |
Why?
|
| Proportional Hazards Models | 11 | 2014 | 12531 | 0.170 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 4925 | 0.170 |
Why?
|
| Seasons | 4 | 2019 | 1522 | 0.170 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2020 | 131 | 0.170 |
Why?
|
| Administration, Oral | 3 | 2024 | 4035 | 0.170 |
Why?
|
| Child | 47 | 2022 | 79806 | 0.170 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2020 | 200 | 0.170 |
Why?
|
| HIV Reverse Transcriptase | 4 | 2011 | 212 | 0.160 |
Why?
|
| Occupational Exposure | 3 | 2014 | 1809 | 0.160 |
Why?
|
| Adolescent | 45 | 2023 | 87810 | 0.160 |
Why?
|
| Hair Follicle | 1 | 2021 | 210 | 0.160 |
Why?
|
| Vaccines, Conjugate | 1 | 2020 | 328 | 0.160 |
Why?
|
| Time Factors | 18 | 2023 | 40165 | 0.160 |
Why?
|
| Pharmacokinetics | 2 | 2010 | 86 | 0.160 |
Why?
|
| Flavonols | 1 | 2019 | 83 | 0.160 |
Why?
|
| DNA, Viral | 4 | 2021 | 2194 | 0.160 |
Why?
|
| England | 1 | 2020 | 526 | 0.160 |
Why?
|
| Young Adult | 25 | 2023 | 58741 | 0.160 |
Why?
|
| Sensitivity and Specificity | 7 | 2020 | 14660 | 0.160 |
Why?
|
| Dietary Supplements | 4 | 2022 | 3392 | 0.160 |
Why?
|
| Benzimidazoles | 3 | 2019 | 858 | 0.160 |
Why?
|
| Virginia | 2 | 2015 | 116 | 0.160 |
Why?
|
| State Medicine | 1 | 2020 | 213 | 0.160 |
Why?
|
| Immunization, Passive | 2 | 2019 | 616 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 1827 | 0.150 |
Why?
|
| Weight Gain | 4 | 2019 | 2347 | 0.150 |
Why?
|
| Tanzania | 6 | 2023 | 1383 | 0.150 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 368 | 0.150 |
Why?
|
| Genes, pol | 1 | 2018 | 52 | 0.150 |
Why?
|
| Morphogenesis | 2 | 2021 | 740 | 0.150 |
Why?
|
| Pancreatitis, Acute Necrotizing | 3 | 2007 | 173 | 0.150 |
Why?
|
| Epidermis | 1 | 2021 | 529 | 0.150 |
Why?
|
| Deoxycytidine | 6 | 2014 | 873 | 0.150 |
Why?
|
| Amantadine | 1 | 2017 | 57 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2001 | 629 | 0.150 |
Why?
|
| Risk Factors | 27 | 2023 | 74359 | 0.150 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 279 | 0.150 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2022 | 420 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 2 | 2016 | 1056 | 0.140 |
Why?
|
| Multivariate Analysis | 14 | 2014 | 12159 | 0.140 |
Why?
|
| Universities | 3 | 2022 | 992 | 0.140 |
Why?
|
| Maternal-Fetal Exchange | 3 | 2016 | 463 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 1 | 2020 | 397 | 0.140 |
Why?
|
| Voice | 1 | 2020 | 267 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 9 | 2024 | 9185 | 0.140 |
Why?
|
| Salvage Therapy | 2 | 2018 | 1268 | 0.140 |
Why?
|
| Iloprost | 1 | 2016 | 25 | 0.140 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 141 | 0.130 |
Why?
|
| Child Development | 7 | 2014 | 2285 | 0.130 |
Why?
|
| Statistics as Topic | 3 | 2000 | 2362 | 0.130 |
Why?
|
| Nucleosides | 2 | 2011 | 131 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2012 | 4897 | 0.130 |
Why?
|
| Saquinavir | 2 | 2007 | 29 | 0.130 |
Why?
|
| Risk Assessment | 7 | 2018 | 24123 | 0.130 |
Why?
|
| Disease Progression | 18 | 2020 | 13502 | 0.130 |
Why?
|
| RNA | 5 | 2023 | 2722 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2019 | 457 | 0.130 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 14495 | 0.130 |
Why?
|
| Condoms | 2 | 2009 | 315 | 0.130 |
Why?
|
| Interferons | 1 | 2019 | 705 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 1993 | 105 | 0.130 |
Why?
|
| Muscular Diseases | 2 | 2016 | 551 | 0.130 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2016 | 103 | 0.120 |
Why?
|
| Drug Administration Schedule | 11 | 2019 | 4899 | 0.120 |
Why?
|
| Prenatal Diagnosis | 2 | 2015 | 1264 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 5 | 2021 | 7408 | 0.120 |
Why?
|
| Hospitalization | 7 | 2024 | 10790 | 0.120 |
Why?
|
| Thailand | 4 | 2020 | 289 | 0.120 |
Why?
|
| Lactobacillus acidophilus | 1 | 1994 | 21 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 2 | 2017 | 1722 | 0.120 |
Why?
|
| Cohort Studies | 23 | 2020 | 41335 | 0.120 |
Why?
|
| Dependovirus | 1 | 2020 | 709 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 3201 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 36290 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2023 | 1055 | 0.120 |
Why?
|
| Bacteriocins | 1 | 1994 | 88 | 0.120 |
Why?
|
| Skinfold Thickness | 2 | 2013 | 158 | 0.120 |
Why?
|
| Morbidity | 1 | 2020 | 1765 | 0.120 |
Why?
|
| Medication Adherence | 4 | 2021 | 2165 | 0.120 |
Why?
|
| Neutropenia | 3 | 2017 | 884 | 0.120 |
Why?
|
| Adenine | 6 | 2018 | 975 | 0.120 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 586 | 0.120 |
Why?
|
| Wound Healing | 2 | 2021 | 2788 | 0.120 |
Why?
|
| AIDS Dementia Complex | 3 | 2004 | 153 | 0.110 |
Why?
|
| Diarrhea | 1 | 2020 | 1319 | 0.110 |
Why?
|
| Body Composition | 3 | 2019 | 2419 | 0.110 |
Why?
|
| beta-Lactam Resistance | 1 | 2014 | 74 | 0.110 |
Why?
|
| Acinetobacter Infections | 1 | 2014 | 71 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2017 | 504 | 0.110 |
Why?
|
| beta-Thalassemia | 1 | 2016 | 235 | 0.110 |
Why?
|
| Pancreatic Diseases | 1 | 1995 | 343 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2013 | 662 | 0.110 |
Why?
|
| Microcirculation | 1 | 2018 | 1278 | 0.110 |
Why?
|
| Carbapenems | 1 | 2014 | 123 | 0.110 |
Why?
|
| Genotype | 9 | 2017 | 12960 | 0.110 |
Why?
|
| Clofibrate | 1 | 1992 | 4 | 0.110 |
Why?
|
| Pregnancy Outcome | 4 | 2024 | 2907 | 0.110 |
Why?
|
| Atrial Fibrillation | 2 | 2012 | 5209 | 0.110 |
Why?
|
| Genitalia, Male | 1 | 2013 | 87 | 0.110 |
Why?
|
| Vitamin D Deficiency | 2 | 2014 | 1379 | 0.110 |
Why?
|
| Acinetobacter baumannii | 1 | 2014 | 115 | 0.110 |
Why?
|
| Europe | 3 | 2015 | 3441 | 0.110 |
Why?
|
| Oxidative Stress | 3 | 2021 | 3106 | 0.110 |
Why?
|
| Homicide | 1 | 2015 | 295 | 0.100 |
Why?
|
| Cross-Sectional Studies | 11 | 2023 | 25942 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 4 | 2015 | 5508 | 0.100 |
Why?
|
| Arthritis, Infectious | 1 | 2016 | 345 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2016 | 419 | 0.100 |
Why?
|
| Survival | 1 | 1992 | 161 | 0.100 |
Why?
|
| Fires | 1 | 2013 | 169 | 0.100 |
Why?
|
| Safety | 1 | 2017 | 1148 | 0.100 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 121 | 0.100 |
Why?
|
| Regeneration | 1 | 2021 | 1506 | 0.100 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 20080 | 0.100 |
Why?
|
| Genitalia, Female | 1 | 2013 | 147 | 0.100 |
Why?
|
| Health Resources | 1 | 2018 | 935 | 0.100 |
Why?
|
| Alkynes | 4 | 2020 | 313 | 0.100 |
Why?
|
| Prospective Studies | 22 | 2020 | 54303 | 0.100 |
Why?
|
| Autoantibodies | 2 | 2021 | 2118 | 0.100 |
Why?
|
| Carotenoids | 1 | 2015 | 620 | 0.100 |
Why?
|
| Drug Combinations | 4 | 2020 | 2025 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 978 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2015 | 674 | 0.100 |
Why?
|
| Outpatients | 3 | 2024 | 1607 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 782 | 0.100 |
Why?
|
| United States | 22 | 2022 | 72461 | 0.100 |
Why?
|
| Virus Replication | 4 | 2012 | 2432 | 0.100 |
Why?
|
| Cyclopropanes | 4 | 2020 | 431 | 0.100 |
Why?
|
| Likelihood Functions | 4 | 2013 | 987 | 0.090 |
Why?
|
| Genetic Variation | 4 | 2018 | 6551 | 0.090 |
Why?
|
| Social Support | 2 | 2014 | 2145 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2021 | 8555 | 0.090 |
Why?
|
| Choline | 1 | 2013 | 513 | 0.090 |
Why?
|
| Lipids | 3 | 2016 | 3336 | 0.090 |
Why?
|
| Pesticides | 1 | 2013 | 293 | 0.090 |
Why?
|
| Inhalation Exposure | 1 | 2014 | 429 | 0.090 |
Why?
|
| Clinical Protocols | 3 | 2007 | 1440 | 0.090 |
Why?
|
| Steroids | 1 | 2016 | 928 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2020 | 3528 | 0.090 |
Why?
|
| Prognosis | 8 | 2020 | 29658 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 9530 | 0.090 |
Why?
|
| Case-Control Studies | 9 | 2018 | 22053 | 0.090 |
Why?
|
| Communication Disorders | 1 | 2011 | 50 | 0.090 |
Why?
|
| Culture | 1 | 2014 | 622 | 0.090 |
Why?
|
| Waist Circumference | 2 | 2013 | 926 | 0.090 |
Why?
|
| Drugs, Generic | 1 | 2015 | 448 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2018 | 2417 | 0.090 |
Why?
|
| Self Efficacy | 1 | 2014 | 630 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 2020 | 3380 | 0.090 |
Why?
|
| Developing Countries | 6 | 2020 | 2868 | 0.090 |
Why?
|
| Developmental Disabilities | 2 | 2016 | 1504 | 0.090 |
Why?
|
| Microscopy | 1 | 2015 | 885 | 0.090 |
Why?
|
| Ferritins | 2 | 2022 | 597 | 0.080 |
Why?
|
| Sexual Behavior | 3 | 2009 | 2086 | 0.080 |
Why?
|
| Algorithms | 4 | 2020 | 13981 | 0.080 |
Why?
|
| Virology | 1 | 2009 | 74 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2018 | 6544 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2019 | 3215 | 0.080 |
Why?
|
| Sex Factors | 6 | 2020 | 10547 | 0.080 |
Why?
|
| Methotrexate | 1 | 2015 | 1719 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2021 | 1949 | 0.080 |
Why?
|
| Vitamin D | 2 | 2014 | 3291 | 0.080 |
Why?
|
| Body Height | 4 | 2016 | 1570 | 0.080 |
Why?
|
| Stavudine | 3 | 2005 | 84 | 0.080 |
Why?
|
| Body Mass Index | 4 | 2015 | 12914 | 0.080 |
Why?
|
| International Cooperation | 1 | 2015 | 1433 | 0.080 |
Why?
|
| Hernia, Umbilical | 1 | 1989 | 102 | 0.080 |
Why?
|
| Argentina | 2 | 2020 | 245 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 1109 | 0.080 |
Why?
|
| Health Status | 2 | 2020 | 4081 | 0.080 |
Why?
|
| Linear Models | 6 | 2014 | 5877 | 0.080 |
Why?
|
| Emotions | 1 | 2020 | 2734 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 6853 | 0.080 |
Why?
|
| Inflammation | 5 | 2022 | 10756 | 0.070 |
Why?
|
| HIV Core Protein p24 | 3 | 1998 | 245 | 0.070 |
Why?
|
| Infant Formula | 1 | 2009 | 193 | 0.070 |
Why?
|
| Robotics | 1 | 2015 | 874 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 4 | 2020 | 6068 | 0.070 |
Why?
|
| Follow-Up Studies | 17 | 2014 | 39261 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 1995 | 1403 | 0.070 |
Why?
|
| Body Weight | 5 | 2016 | 4611 | 0.070 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 1441 | 0.070 |
Why?
|
| Exanthema | 1 | 2012 | 504 | 0.070 |
Why?
|
| Anthropometry | 4 | 2016 | 1348 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2006 | 708 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2020 | 3598 | 0.070 |
Why?
|
| Rural Population | 1 | 1997 | 2268 | 0.070 |
Why?
|
| Internet | 1 | 2019 | 3078 | 0.070 |
Why?
|
| Hemoglobins | 3 | 2022 | 1521 | 0.070 |
Why?
|
| Fatty Acids | 1 | 2015 | 1804 | 0.070 |
Why?
|
| Glucocorticoids | 2 | 2015 | 2145 | 0.070 |
Why?
|
| Africa South of the Sahara | 3 | 2014 | 742 | 0.070 |
Why?
|
| Lung | 3 | 2014 | 9994 | 0.070 |
Why?
|
| Spirometry | 3 | 2014 | 924 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 1997 | 2869 | 0.070 |
Why?
|
| Pre-Eclampsia | 2 | 2013 | 1229 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 4291 | 0.070 |
Why?
|
| Age Factors | 9 | 2013 | 18416 | 0.070 |
Why?
|
| Occlusive Dressings | 1 | 2006 | 52 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 981 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2018 | 3562 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2011 | 965 | 0.070 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2011 | 599 | 0.070 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2006 | 26 | 0.070 |
Why?
|
| Adiposity | 2 | 2013 | 1858 | 0.070 |
Why?
|
| Asthma | 3 | 2022 | 6172 | 0.070 |
Why?
|
| Homeostasis | 2 | 2015 | 3306 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 2315 | 0.060 |
Why?
|
| Forecasting | 1 | 2015 | 2932 | 0.060 |
Why?
|
| Placebos | 3 | 2010 | 1668 | 0.060 |
Why?
|
| Nitriles | 2 | 2022 | 956 | 0.060 |
Why?
|
| Half-Life | 2 | 2023 | 652 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2009 | 639 | 0.060 |
Why?
|
| Kinetics | 2 | 2023 | 6377 | 0.060 |
Why?
|
| Nutritional Support | 1 | 2007 | 172 | 0.060 |
Why?
|
| Herpes Genitalis | 1 | 2007 | 142 | 0.060 |
Why?
|
| Mental Health | 1 | 2020 | 3213 | 0.060 |
Why?
|
| Hemocytes | 1 | 2005 | 44 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2014 | 1131 | 0.060 |
Why?
|
| Data Collection | 1 | 2015 | 3315 | 0.060 |
Why?
|
| Varicose Ulcer | 1 | 2006 | 54 | 0.060 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 15757 | 0.060 |
Why?
|
| Herpesvirus 2, Human | 1 | 2007 | 191 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 1992 | 1155 | 0.060 |
Why?
|
| Virus Internalization | 1 | 2009 | 494 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2006 | 176 | 0.060 |
Why?
|
| Nurses | 1 | 2015 | 2467 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 2 | 2024 | 908 | 0.060 |
Why?
|
| Leptin | 1 | 2013 | 1591 | 0.060 |
Why?
|
| Endoscopy | 1 | 2015 | 1838 | 0.060 |
Why?
|
| Growth Disorders | 1 | 2010 | 653 | 0.060 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2006 | 166 | 0.060 |
Why?
|
| Drug Costs | 2 | 2015 | 1185 | 0.060 |
Why?
|
| Diet, Fat-Restricted | 1 | 2007 | 330 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 3164 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2016 | 2511 | 0.060 |
Why?
|
| Receptors, HIV | 1 | 2005 | 159 | 0.060 |
Why?
|
| Cross-Over Studies | 3 | 2009 | 2061 | 0.060 |
Why?
|
| Protease Inhibitors | 2 | 2023 | 755 | 0.060 |
Why?
|
| Obesity | 3 | 2019 | 12922 | 0.060 |
Why?
|
| Iron | 2 | 2023 | 1786 | 0.060 |
Why?
|
| Integumentary System | 1 | 2004 | 2 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 12293 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 2 | 2018 | 416 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2016 | 2064 | 0.060 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2004 | 82 | 0.060 |
Why?
|
| Fetal Diseases | 1 | 1989 | 911 | 0.060 |
Why?
|
| Growth and Development | 1 | 2004 | 47 | 0.060 |
Why?
|
| Occupations | 1 | 2006 | 515 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2020 | 643 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2008 | 1928 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 2250 | 0.060 |
Why?
|
| Mutation | 6 | 2022 | 29932 | 0.060 |
Why?
|
| Blood Pressure | 3 | 2014 | 8525 | 0.060 |
Why?
|
| Restaurants | 1 | 2006 | 230 | 0.060 |
Why?
|
| Prevalence | 6 | 2022 | 15687 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2020 | 4647 | 0.050 |
Why?
|
| Control Groups | 1 | 2023 | 104 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2006 | 605 | 0.050 |
Why?
|
| Mitochondrial Diseases | 1 | 2007 | 340 | 0.050 |
Why?
|
| Debridement | 1 | 2006 | 492 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 1075 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2014 | 2093 | 0.050 |
Why?
|
| Psoriasis | 1 | 2011 | 940 | 0.050 |
Why?
|
| Dermatophagoides pteronyssinus | 1 | 2022 | 11 | 0.050 |
Why?
|
| Alanine Transaminase | 2 | 2018 | 606 | 0.050 |
Why?
|
| Internationality | 2 | 2018 | 1004 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2007 | 6238 | 0.050 |
Why?
|
| Mass Screening | 1 | 2018 | 5423 | 0.050 |
Why?
|
| Hospitals, Psychiatric | 1 | 2004 | 320 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2021 | 5961 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2009 | 608 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 1933 | 0.050 |
Why?
|
| Vertebrates | 1 | 2004 | 228 | 0.050 |
Why?
|
| Sampling Studies | 2 | 1997 | 613 | 0.050 |
Why?
|
| Social Perception | 1 | 2006 | 431 | 0.050 |
Why?
|
| Biological Evolution | 2 | 2009 | 1074 | 0.050 |
Why?
|
| Sierra Leone | 1 | 2022 | 168 | 0.050 |
Why?
|
| Pyroglyphidae | 1 | 2022 | 88 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 1989 | 1415 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 3696 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2003 | 421 | 0.050 |
Why?
|
| Cognition | 3 | 2013 | 6957 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 728 | 0.050 |
Why?
|
| Malaria | 1 | 2011 | 1226 | 0.050 |
Why?
|
| Pancreatitis | 2 | 2002 | 1100 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2008 | 1617 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 4713 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2566 | 0.050 |
Why?
|
| Murinae | 1 | 2021 | 18 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 4048 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 3839 | 0.050 |
Why?
|
| Depression, Postpartum | 1 | 2006 | 345 | 0.050 |
Why?
|
| Forced Expiratory Volume | 4 | 2014 | 1809 | 0.050 |
Why?
|
| Mathematics | 2 | 1995 | 707 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 1994 | 3826 | 0.050 |
Why?
|
| Retrospective Studies | 11 | 2023 | 80372 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 2 | 1992 | 345 | 0.050 |
Why?
|
| Africa | 2 | 2014 | 705 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2008 | 1341 | 0.050 |
Why?
|
| Diet Surveys | 2 | 2015 | 1161 | 0.050 |
Why?
|
| Ceftriaxone | 1 | 2021 | 176 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2005 | 919 | 0.050 |
Why?
|
| Platelet Count | 2 | 2013 | 777 | 0.050 |
Why?
|
| Microscopy, Atomic Force | 1 | 2021 | 247 | 0.040 |
Why?
|
| Spleen Focus-Forming Viruses | 1 | 2020 | 16 | 0.040 |
Why?
|
| Biological Assay | 1 | 2023 | 630 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2022 | 461 | 0.040 |
Why?
|
| Bone Density | 1 | 2013 | 3534 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2005 | 1091 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2016 | 4783 | 0.040 |
Why?
|
| Luciferases, Firefly | 1 | 2020 | 37 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2013 | 732 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2015 | 3763 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2004 | 1130 | 0.040 |
Why?
|
| Esophageal and Gastric Varices | 2 | 1993 | 208 | 0.040 |
Why?
|
| Semen | 1 | 2022 | 346 | 0.040 |
Why?
|
| Computer Simulation | 3 | 2010 | 6218 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2012 | 3600 | 0.040 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 1999 | 119 | 0.040 |
Why?
|
| Selection, Genetic | 2 | 2009 | 869 | 0.040 |
Why?
|
| Chemokines | 1 | 2004 | 962 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2012 | 3905 | 0.040 |
Why?
|
| Mothers | 3 | 2020 | 2186 | 0.040 |
Why?
|
| Lymphoma | 1 | 2009 | 1898 | 0.040 |
Why?
|
| Plant Bark | 1 | 2019 | 9 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2021 | 5201 | 0.040 |
Why?
|
| Grape Seed Extract | 1 | 2019 | 11 | 0.040 |
Why?
|
| Pinus | 1 | 2019 | 14 | 0.040 |
Why?
|
| Area Under Curve | 3 | 2010 | 1636 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2007 | 1992 | 0.040 |
Why?
|
| Insulin Resistance | 3 | 2021 | 3959 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2022 | 608 | 0.040 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 216 | 0.040 |
Why?
|
| Phosphates | 1 | 2022 | 772 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2013 | 4412 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 427 | 0.040 |
Why?
|
| Smoking | 3 | 2013 | 9073 | 0.040 |
Why?
|
| Length of Stay | 4 | 2017 | 6479 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2022 | 22023 | 0.040 |
Why?
|
| Survivors | 2 | 2022 | 2375 | 0.040 |
Why?
|
| Time | 2 | 2007 | 545 | 0.040 |
Why?
|
| Exercise | 1 | 2015 | 5787 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2021 | 747 | 0.040 |
Why?
|
| Voice Quality | 1 | 2020 | 226 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 2 | 2010 | 114 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 857 | 0.040 |
Why?
|
| Oxazines | 1 | 2020 | 341 | 0.040 |
Why?
|
| Pakistan | 1 | 2019 | 304 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 2 | 2008 | 125 | 0.040 |
Why?
|
| Fluid Therapy | 1 | 2002 | 579 | 0.040 |
Why?
|
| Escherichia coli | 3 | 2017 | 4219 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 769 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2022 | 563 | 0.040 |
Why?
|
| Recurrence | 2 | 2022 | 8482 | 0.040 |
Why?
|
| Pyridazines | 1 | 2019 | 200 | 0.040 |
Why?
|
| Regenerative Medicine | 1 | 2021 | 307 | 0.040 |
Why?
|
| Patient Dropouts | 2 | 1997 | 412 | 0.040 |
Why?
|
| Dideoxynucleosides | 1 | 1998 | 132 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 2942 | 0.040 |
Why?
|
| Telemedicine | 1 | 2015 | 3018 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2013 | 1544 | 0.040 |
Why?
|
| Pain | 2 | 2023 | 5066 | 0.040 |
Why?
|
| Medical Errors | 1 | 2005 | 1255 | 0.040 |
Why?
|
| Resuscitation | 1 | 2002 | 661 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 5397 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2020 | 9716 | 0.040 |
Why?
|
| Lactation | 1 | 2019 | 397 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2018 | 301 | 0.030 |
Why?
|
| Panama | 1 | 2016 | 28 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2021 | 827 | 0.030 |
Why?
|
| Intelligence | 2 | 2013 | 921 | 0.030 |
Why?
|
| El Salvador | 1 | 2016 | 33 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 8010 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2002 | 1869 | 0.030 |
Why?
|
| Ethics, Medical | 2 | 1993 | 783 | 0.030 |
Why?
|
| Hand | 1 | 2021 | 903 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 1710 | 0.030 |
Why?
|
| Hepatitis | 1 | 2018 | 230 | 0.030 |
Why?
|
| Multiple Organ Failure | 2 | 2013 | 386 | 0.030 |
Why?
|
| South Africa | 2 | 2012 | 1821 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 1699 | 0.030 |
Why?
|
| Zalcitabine | 3 | 2000 | 43 | 0.030 |
Why?
|
| Electric Impedance | 2 | 2010 | 755 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2019 | 658 | 0.030 |
Why?
|
| Travel | 1 | 2021 | 785 | 0.030 |
Why?
|
| Cytokines | 1 | 2010 | 7343 | 0.030 |
Why?
|
| Neonatal Screening | 1 | 2020 | 595 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2022 | 1300 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2024 | 2440 | 0.030 |
Why?
|
| Bangladesh | 1 | 1997 | 728 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3276 | 0.030 |
Why?
|
| Receptors, CCR2 | 2 | 2008 | 215 | 0.030 |
Why?
|
| Patient Compliance | 4 | 2010 | 2688 | 0.030 |
Why?
|
| Mexico | 1 | 2017 | 760 | 0.030 |
Why?
|
| Arthrography | 1 | 2015 | 149 | 0.030 |
Why?
|
| Pancreas | 1 | 2002 | 1677 | 0.030 |
Why?
|
| Pyridones | 1 | 2020 | 792 | 0.030 |
Why?
|
| Risk | 3 | 2018 | 9631 | 0.030 |
Why?
|
| Dyspnea | 1 | 2023 | 1352 | 0.030 |
Why?
|
| Headache | 1 | 2023 | 1249 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2019 | 580 | 0.030 |
Why?
|
| Pyridines | 2 | 1997 | 2879 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2008 | 2809 | 0.030 |
Why?
|
| Animals | 8 | 2022 | 167963 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1995 | 186 | 0.030 |
Why?
|
| Life Expectancy | 2 | 2012 | 1248 | 0.030 |
Why?
|
| Brazil | 2 | 2009 | 1218 | 0.030 |
Why?
|
| Fetal Death | 2 | 2002 | 434 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2008 | 3258 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 2138 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 2852 | 0.030 |
Why?
|
| Adipose Tissue | 2 | 2019 | 3301 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2020 | 2057 | 0.030 |
Why?
|
| Electronics, Medical | 1 | 2014 | 72 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 10827 | 0.030 |
Why?
|
| Anistreplase | 1 | 1993 | 11 | 0.030 |
Why?
|
| Predictive Value of Tests | 6 | 2013 | 15289 | 0.030 |
Why?
|
| Phlebotomy | 1 | 2015 | 137 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2013 | 1343 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2017 | 856 | 0.030 |
Why?
|
| Immunity, Innate | 2 | 2022 | 3047 | 0.030 |
Why?
|
| Pyrethrins | 1 | 2013 | 44 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2008 | 13451 | 0.030 |
Why?
|
| Mycoses | 1 | 1997 | 387 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2018 | 1428 | 0.030 |
Why?
|
| Monitoring, Immunologic | 1 | 1994 | 98 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 1289 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2008 | 6381 | 0.030 |
Why?
|
| Triglycerides | 2 | 2014 | 2476 | 0.030 |
Why?
|
| Nutrition Policy | 1 | 1997 | 470 | 0.030 |
Why?
|
| Mice | 4 | 2022 | 81208 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 58995 | 0.030 |
Why?
|
| Biosensing Techniques | 1 | 2020 | 677 | 0.030 |
Why?
|
| Placenta | 1 | 2022 | 1702 | 0.030 |
Why?
|
| Hypertension | 2 | 2008 | 8594 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2022 | 3442 | 0.030 |
Why?
|
| Lactobacillus | 1 | 1994 | 204 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2021 | 1370 | 0.030 |
Why?
|
| Washington | 1 | 2013 | 312 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 2203 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 1758 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 17624 | 0.030 |
Why?
|
| Betaine | 1 | 2013 | 89 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2021 | 1057 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2014 | 216 | 0.030 |
Why?
|
| Organophosphorus Compounds | 1 | 2013 | 202 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2007 | 791 | 0.030 |
Why?
|
| Breath Tests | 1 | 2014 | 297 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 600 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 4541 | 0.030 |
Why?
|
| Software | 2 | 1999 | 4419 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2023 | 2781 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 1902 | 0.030 |
Why?
|
| Acute Disease | 2 | 2019 | 7269 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2015 | 582 | 0.030 |
Why?
|
| Eating | 1 | 2019 | 1539 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2019 | 1334 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 2013 | 222 | 0.020 |
Why?
|
| Models, Biological | 3 | 2012 | 9467 | 0.020 |
Why?
|
| Cholesterol, LDL | 2 | 2014 | 2420 | 0.020 |
Why?
|
| Injections, Subcutaneous | 2 | 2004 | 680 | 0.020 |
Why?
|
| Bilirubin | 1 | 1993 | 438 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 1296 | 0.020 |
Why?
|
| Vitamin A | 1 | 2015 | 613 | 0.020 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1992 | 309 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2015 | 727 | 0.020 |
Why?
|
| Parity | 1 | 2015 | 925 | 0.020 |
Why?
|
| Models, Economic | 1 | 2015 | 719 | 0.020 |
Why?
|
| beta-Alanine | 1 | 2012 | 82 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 2 | 2005 | 877 | 0.020 |
Why?
|
| Comorbidity | 3 | 2016 | 10551 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2015 | 670 | 0.020 |
Why?
|
| Demography | 2 | 2006 | 1650 | 0.020 |
Why?
|
| Heterozygote | 1 | 1998 | 2798 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2020 | 2488 | 0.020 |
Why?
|
| Eclampsia | 1 | 2011 | 56 | 0.020 |
Why?
|
| Aerosols | 1 | 2014 | 632 | 0.020 |
Why?
|
| Feces | 1 | 2017 | 1455 | 0.020 |
Why?
|
| South America | 1 | 2011 | 181 | 0.020 |
Why?
|
| California | 1 | 2015 | 1416 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2013 | 965 | 0.020 |
Why?
|
| Parturition | 1 | 2014 | 446 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2004 | 4550 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2011 | 257 | 0.020 |
Why?
|
| Myocardial Infarction | 2 | 2007 | 11891 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1995 | 1630 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2014 | 540 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2005 | 4360 | 0.020 |
Why?
|
| Species Specificity | 1 | 1994 | 2418 | 0.020 |
Why?
|
| Carbon | 1 | 2014 | 669 | 0.020 |
Why?
|
| Single-Blind Method | 2 | 2005 | 1578 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 386 | 0.020 |
Why?
|
| Bahamas | 1 | 2009 | 9 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2013 | 522 | 0.020 |
Why?
|
| Diastole | 1 | 1992 | 788 | 0.020 |
Why?
|
| Colombia | 1 | 2010 | 276 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 2502 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1994 | 1600 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 1989 | 136 | 0.020 |
Why?
|
| Atrial Flutter | 1 | 2012 | 258 | 0.020 |
Why?
|
| Emotional Intelligence | 1 | 2011 | 135 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 558 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2014 | 757 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2010 | 208 | 0.020 |
Why?
|
| Particle Size | 1 | 2014 | 1644 | 0.020 |
Why?
|
| Virus Latency | 1 | 2012 | 362 | 0.020 |
Why?
|
| Survival Rate | 3 | 2005 | 12808 | 0.020 |
Why?
|
| Life Change Events | 1 | 2014 | 952 | 0.020 |
Why?
|
| Vitamin K | 1 | 2012 | 321 | 0.020 |
Why?
|
| Viral Tropism | 1 | 2009 | 102 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 1166 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2013 | 732 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2011 | 650 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 926 | 0.020 |
Why?
|
| Electric Countershock | 1 | 2012 | 537 | 0.020 |
Why?
|
| Perinatal Care | 1 | 2011 | 242 | 0.020 |
Why?
|
| Somatostatin | 1 | 1990 | 447 | 0.020 |
Why?
|
| Entropy | 1 | 2009 | 210 | 0.020 |
Why?
|
| Public Health | 1 | 2022 | 2653 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 5785 | 0.020 |
Why?
|
| Creatinine | 1 | 2014 | 1903 | 0.020 |
Why?
|
| Phenotype | 4 | 2002 | 16546 | 0.020 |
Why?
|
| Safe Sex | 1 | 2009 | 139 | 0.020 |
Why?
|
| Violence | 1 | 2014 | 927 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2005 | 7850 | 0.020 |
Why?
|
| Women's Health | 1 | 1997 | 2056 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2011 | 1018 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1993 | 1259 | 0.020 |
Why?
|
| India | 1 | 2014 | 2336 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 1817 | 0.020 |
Why?
|
| Death | 1 | 2012 | 678 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2004 | 15789 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 494 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 11071 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 1628 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 21025 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2009 | 524 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 1189 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 1997 | 2061 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2021 | 23376 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2015 | 1129 | 0.020 |
Why?
|
| North America | 1 | 2011 | 1284 | 0.020 |
Why?
|
| Educational Status | 1 | 2015 | 2515 | 0.020 |
Why?
|
| Gene Expression | 1 | 2020 | 7588 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2013 | 1736 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 1992 | 978 | 0.020 |
Why?
|
| Firearms | 1 | 2014 | 625 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3520 | 0.020 |
Why?
|
| Social Responsibility | 1 | 1989 | 386 | 0.020 |
Why?
|
| Insulin | 1 | 2021 | 6597 | 0.020 |
Why?
|
| Resilience, Psychological | 1 | 2014 | 768 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 2 | 1999 | 144 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2006 | 115 | 0.020 |
Why?
|
| Growth | 1 | 2008 | 365 | 0.020 |
Why?
|
| Milk | 1 | 2009 | 443 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 415 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 895 | 0.020 |
Why?
|
| Folic Acid | 1 | 2013 | 1309 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2008 | 437 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2007 | 208 | 0.020 |
Why?
|
| Child Behavior Disorders | 1 | 2011 | 805 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 22072 | 0.020 |
Why?
|
| Hemolymph | 1 | 2005 | 27 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 7593 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 2622 | 0.020 |
Why?
|
| Fat Body | 1 | 2005 | 31 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2009 | 899 | 0.020 |
Why?
|
| Budesonide | 2 | 1999 | 158 | 0.020 |
Why?
|
| Premenopause | 1 | 2009 | 1038 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 9411 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 2514 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 2176 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2021 | 3517 | 0.010 |
Why?
|
| Students | 1 | 2014 | 1730 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2008 | 638 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2007 | 506 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 1993 | 2108 | 0.010 |
Why?
|
| Psychology | 1 | 2006 | 355 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2004 | 6796 | 0.010 |
Why?
|
| Sexual Partners | 1 | 2009 | 753 | 0.010 |
Why?
|
| Random Allocation | 1 | 1988 | 2394 | 0.010 |
Why?
|
| Health Surveys | 1 | 2014 | 4063 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2008 | 2753 | 0.010 |
Why?
|
| Checklist | 1 | 2011 | 827 | 0.010 |
Why?
|
| DNA Primers | 1 | 2008 | 2819 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2008 | 667 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2007 | 1991 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2008 | 1526 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1990 | 1131 | 0.010 |
Why?
|
| Cholesterol | 1 | 1992 | 2924 | 0.010 |
Why?
|
| New England | 1 | 2006 | 1050 | 0.010 |
Why?
|
| Memory | 1 | 2013 | 2179 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 12626 | 0.010 |
Why?
|
| Biopsy | 1 | 2015 | 6771 | 0.010 |
Why?
|
| Cause of Death | 1 | 1993 | 3725 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 4166 | 0.010 |
Why?
|
| Thymidine | 1 | 2002 | 299 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2004 | 394 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1987 | 755 | 0.010 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2004 | 303 | 0.010 |
Why?
|
| Apgar Score | 1 | 2002 | 126 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2005 | 859 | 0.010 |
Why?
|
| Glucose | 1 | 2014 | 4351 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2003 | 454 | 0.010 |
Why?
|
| Psychometrics | 1 | 2011 | 3051 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2008 | 1725 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 1697 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 2004 | 321 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 1987 | 831 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 1553 | 0.010 |
Why?
|
| Hematocrit | 1 | 2002 | 629 | 0.010 |
Why?
|
| Postmenopause | 1 | 2009 | 2509 | 0.010 |
Why?
|
| Alleles | 1 | 2011 | 6898 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8803 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2015 | 9287 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4573 | 0.010 |
Why?
|
| Aspirin | 1 | 2012 | 3364 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2007 | 1535 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2005 | 1535 | 0.010 |
Why?
|
| Administration, Inhalation | 2 | 1992 | 1156 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 1602 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1987 | 2693 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 1411 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7806 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11712 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 3800 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1998 | 151 | 0.010 |
Why?
|
| Liver | 2 | 2006 | 7509 | 0.010 |
Why?
|
| Urban Population | 1 | 2006 | 2022 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 12446 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2002 | 632 | 0.010 |
Why?
|
| Giant Cells | 1 | 1998 | 185 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 2002 | 859 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1987 | 2313 | 0.010 |
Why?
|
| Necrosis | 1 | 2002 | 1612 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2004 | 1167 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3775 | 0.010 |
Why?
|
| Motor Activity | 1 | 2007 | 2687 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1998 | 691 | 0.010 |
Why?
|
| RNA Interference | 1 | 2005 | 2846 | 0.010 |
Why?
|
| Delivery, Obstetric | 1 | 2004 | 932 | 0.010 |
Why?
|
| Gestational Age | 1 | 2005 | 3565 | 0.010 |
Why?
|
| Decision Making | 1 | 2009 | 3925 | 0.010 |
Why?
|
| Erythema | 1 | 1996 | 262 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 1997 | 430 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2006 | 2313 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2007 | 4013 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 5870 | 0.010 |
Why?
|
| Boston | 1 | 2006 | 9280 | 0.010 |
Why?
|
| Terbutaline | 1 | 1992 | 23 | 0.010 |
Why?
|
| Ipratropium | 1 | 1992 | 19 | 0.010 |
Why?
|
| Beclomethasone | 1 | 1992 | 38 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7475 | 0.010 |
Why?
|
| Pregnenediones | 1 | 1992 | 29 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2002 | 2092 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2004 | 5125 | 0.010 |
Why?
|
| Albuterol | 1 | 1992 | 212 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 15620 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1992 | 641 | 0.010 |
Why?
|
| Respiratory Hypersensitivity | 1 | 1992 | 272 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1999 | 1796 | 0.010 |
Why?
|
| Balloon Occlusion | 1 | 1990 | 127 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 1992 | 506 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 1385 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2002 | 18957 | 0.000 |
Why?
|
| Neurons | 1 | 2005 | 9426 | 0.000 |
Why?
|
| Catheterization | 1 | 1990 | 1432 | 0.000 |
Why?
|
| Aging | 1 | 2003 | 8651 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1990 | 1328 | 0.000 |
Why?
|
| Immunization | 1 | 1987 | 1227 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1990 | 8552 | 0.000 |
Why?
|
| Brain | 1 | 2005 | 26951 | 0.000 |
Why?
|
| Periodicals as Topic | 1 | 1987 | 1469 | 0.000 |
Why?
|
| Pneumonia | 1 | 1987 | 2131 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1987 | 10181 | 0.000 |
Why?
|